Rapid Stereomicroscopic Imaging of HER2 Overexpression in Ex Vivo Breast Tissue Using Topically Applied Silica-Based Gold Nanoshells by Bickford, Lissett R. et al.
Hindawi Publishing Corporation
Journal of Oncology
Volume 2012, Article ID 291898, 10 pages
doi:10.1155/2012/291898
Research Article
Rapid Stereomicroscopic Imaging of HER2
Overexpression in ExVivo Breast Tissue Using Topically
Applied Silica-Based Gold Nanoshells
Lissett R. Bickford,1, 2, 3 Robert J. Langsner,1 Joseph Chang,4 Laura C. Kennedy,1, 5
Germaine D. Agollah,6 and Rebekah Drezek1, 7
1Department of Bioengineering, Rice University, 6100 Main Street, MS 142, Houston, TX 77005, USA
2School of Biomedical Engineering and Sciences, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA
3Department of Mechanical Engineering, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA
4School of Medicine, University of California San Francisco, San Francisco, CA 94143, USA
5School of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
6Department of Chemistry and Process Development, Nanospectra Biosciences, Inc., Houston, TX 77054, USA
7Department of Electrical and Computer Engineering, Rice University, Houston, TX 77005, USA
Correspondence should be addressed to Rebekah Drezek, drezek@rice.edu
Received 5 April 2012; Accepted 11 September 2012
Academic Editor: Jose´ Marı´a Benlloch
Copyright © 2012 Lissett R. Bickford et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Tumor margin detection for patients undergoing breast conservation surgery primarily occurs postoperatively. Previously, we
demonstrated that gold nanoshells rapidly enhance contrast of HER2 overexpression in ex vivo tissue sections. Our ultimate
objective, however, is to discern HER2 overexpressing tissue from normal tissue in whole, nonsectioned, specimens to facilitate
rapid diagnoses. Here, we use targeted nanoshells to quickly and eﬀectively visualize HER2 receptor expression in intact ex vivo
human breast tissue specimens. Punch biopsies of human breast tissue were analyzed after a brief 5-minute incubation with and
without HER2-targeted silica-gold nanoshells using two-photon microscopy and stereomicroscopy. Labeling was subsequently
verified using reflectance confocal microscopy, darkfield hyperspectral imaging, and immunohistochemistry to confirm levels
of HER2 expression. Our results suggest that anti-HER2 nanoshells used in tandem with a near-infrared reflectance confocal
microscope and a standard stereomicroscope may potentially be used to discern HER2-overexpressing cancerous tissue from
normal tissue in near real time and oﬀer a rapid supplement to current diagnostic techniques.
1. Introduction
Currently, breast cancer is the second leading cause of cancer-
related deaths in women, and it accounts for approximately
one-third of all cancers diagnosed in women in the United
States [1]. To reduce cancer recurrence and progression, can-
cerous tissue must be completely eliminated, regardless of
grade [2]. Surgical breast cancer therapy focuses on remov-
ing the primary tumor and identifying the possibility of
metastatic disease from the evaluation of sentinel lymph
nodes. Although some patients may require modified radical
mastectomy, many patients with less-advanced breast cancer
elect breast-conserving surgery. The presence of a positive
surgical margin during these surgeries has been associated
with lower rates of patient survival [3]. Due to residual
cancer cells being left in many patients that undergo breast
conservation therapy, as many as 40% of patients have
experienced local breast cancer recurrence near the site of the
original tumor [4]. Intraoperative treatment decisions are,
therefore, absolutely critical.
Presently, intraoperative tumor margin detection occurs
primarily in specialized tertiary centers, such as The Uni-
versity of Texas M.D. Anderson Cancer Center (MDACC).
In these centers, the resected tissue receives a preliminary
evaluation by a pathologist while the patient remains in
the operating room; if necessary, additional tissue can be
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removed until the pathologist determines that the tumor
margins are negative. In community hospitals, however,
pathologic analysis of excised tissue only occurs postoper-
atively [5]. Patients who consequently have positive tumor
margins must return for surgical reexcision and receive
increased doses of adjuvant radiation therapy [6, 7]. Thus,
the existence of positive tumor margins portends additional
risks and costs to the patient. Due to the existing limitations
of current intraoperative tumor margin detection, there is
an opportunity to develop superior diagnostic tools to assist
in reducing the recurrence and progression of cancer due to
inadequate tissue removal during primary surgery.
While histologic analysis remains the gold standard for
tumor margin assessment, the macroscopic evaluation of
whole, nonsectioned tissue specimens may also be used
to provide an intraoperative estimate of tumor margin
status prior to subsequent processing. This would be an
invaluable tool in hospitals without onsite pathology suites.
Macroscopic visualization of questionable tissue is attractive
for enhancing the sensitivity and specificity of tumor margin
delineation: if the number of suspicious regions that require
further microscopic processing can be reduced, surgeons and
pathologists can focus their attention and resources on areas
that remain inconclusive. Currently, macroscopic evaluation
only occurs for breast cancer specimens that involve micro-
calcifications or nonpalpable masses and does not occur for
palpable breast masses [8]. For nonpalpable masses that have
been resected, radiographic images are used to determine
the extent of the breast disease and the proximity to the
resected margins. Although specimen radiography appears
to increase the accuracy of tumor margin detection, limita-
tions have been noted. For instance, microcalcifications that
appear as tumor on radiographic images may actually be
areas of lymphocytic accumulation [9]. The use of contrast
agents targeted to specific biomarkers associated with disease
may present an opportunity to increase the sensitivity and
specificity of macroscopic evaluations.
In preceding studies, we confirmed that silica-based gold
nanoshells targeted to the Human Epidermal growth factor
Receptor 2 (HER2) could be used for the rapid contrast
enhancement of both cells [10] and tissue sections [11]
which overexpress HER2 biomarkers. While gold nanoshells
can be conjugated to a variety of biomarkers [12, 13], we have
selected HER2 due to its association with increased cancer
aggression, recurrence, and progression when amplified [14,
15]. Amplification of this cell-surface bound tyrosine kinase
receptor occurs in up to a quarter of all human breast cancer
cases [16]. Importantly, using biomarkers for tumor margin
detection has recently been shown to better identify patients
at high risk of cancer recurrence over standard histological
analysis [17].
To facilitate prompt tumor margin detection intraopera-
tively, the ability to assess tumor margins without physical
sectioning is highly desirable as sectioning may incur signif-
icant time to the surgical procedure [5]. Thus, in this study,
we advance our previous findings by examining the ability to
rapidly target HER2 receptors in intact ex vivo human breast
tissue specimens without sectioning. We first confirm the
predominance of the surface targeting needed to identify the
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Figure 1: Measured extinction spectra of nanoshells with an aver-
age core diameter of 276 nm and average shell thickness of 19 nm.
Insert depicts corresponding image from scanning electron micro-
scopy. Scale bar represents 500 nm.
tumor margins and preferential labeling of HER2-positive
tissue using two photon and hyperspectral imaging. Then,
we demonstrate that anti-HER2-targeted gold nanoshells
can be used as rapid diagnostic imaging agents for HER2
overexpression in intact breast tissue specimens using a
standard stereomicroscope and confirm these results through
reflectance confocal microscopy and immunohistochem-
istry.
2. Materials andMethods
2.1. Nanoshell Fabrication and Antibody Conjugation. Nano-
shells were fabricated as formerly described [18–20], and
only a brief summary will be provided here. Silica cores
were made using the Sto¨ber method [21], in which tetraethyl
orthosilicate was reduced in the presence of ammonium
hydroxide dissolved in 200 proof ethanol. The surfaces of the
cores were then modified by reaction with aminopropyltri-
ethoxysilane (APTES) to functionalize reactive amine groups
on the surface. The final particles were measured by dynamic
light scattering (DLS) to have an average diameter of 276 nm.
Next, gold colloid (∼1–3 nm diameter) was fabricated and
adsorbed onto the surface of the silica cores via the amine
groups to form gold nucleation sites [22]. To fully cover the
surface of the silica cores, additional gold was added to these
nucleation sites via a reduction reaction in which hydrogen
tetrachloroaurate trihydrate (HAuCl43H2O) was dissolved in
potassium carbonate and then added with formaldehyde to
help reduce the gold. After the gold layer over the silica cores
was formed, the spectrum of the final nanoshell solution was
visualized using a UV-VIS spectrophotometer (Varian Cary
300) (Figure 1).
To determine the concentration of nanoshells in solution,
the absorption, scattering, and extinction coeﬃcients were
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determined using Mie theory. The average nanoshell diame-
ter, as validated by scanning electron microscopy (SEM), was
314 nm with a peak surface plasmon resonance at 840 nm.
The concentration of the working nanoshell solution was
approximately 2.0 × 109 particles/mL.
Nanoshells were targeted to biological HER2 antigens
by linking the surfaces of the nanoshells to anti-HER2
antibodies using previously described methods [18]. Prior to
beginning experimental studies, nanoshells were incubated
with an anti-HER2-linker cocktail [18] for 2 hours at 4◦C.
To ensure nanoparticle stabilization in biological media, the
nanoshells were next incubated with a 1mM polyethylene
glycolthiol solution (PEG-SH,MW = 5 kD, Nektar) for 12–16
hours at 4◦C. Next, unbound antibodies and excess PEG-SH
were removed from the nanoshells by centrifugation. Prior
to experimental studies, the nanoshells were resuspended in
antibody diluent (IHC World, pH 7.4) by gentle pipetting to
a final volume of 165 µL.
2.2. Ex Vivo Human Breast Tissue Specimens. Normal and
cancerous (HER2-negative and HER2-positive) breast tissue
specimens were supplied by the Cooperative Human Tissue
Network (CHTN) through a protocol approved by the
Institutional Review Board (IRB). Tissues were designated as
normal or cancerous by pathologists at the medical centers
where the tissue samples were obtained. Additionally, HER2
status was previously determined by pathologists at the
respective medical centers prior to the patients undergoing
any form of medical treatment.
Before use, samples were thawed briefly in a 37◦C water
bath and cut on a disposable cutting board using a 5mm
punch biopsy to maintain size consistency. At least two
punch biopsies were taken from each specimen for control
and experimental conditions. Each cut specimen used was
5mm in diameter with an average thickness of 1mm.
Tissue samples were subsequently incubated in prewarmed
antibody diluent for 1 minute at room temperature with
gentle agitation in a 24-well plate. After prerinsing, the
samples were incubated in either antibody diluent or the
aforementioned targeted-nanoshell cocktail in polyethylene
sample vials (Sigma Aldrich). The vials were placed on a
nutator in an incubator at 37◦C for 5 minutes. After incu-
bation, the tissue samples were removed from the vials and
rinsed 3 times in 1x PBS briefly in a 24-well plate. Samples
were moved to a clean well of 1x PBS prior to imaging.
2.3. Two-Photon Imaging of Human Breast Tissue Specimens.
Both HER2-positive and HER2-negative cancerous sam-
ples were evaluated for surface labeling of HER2-targeted
nanoshells by employing two-photon imaging of intact
breast tissue specimens. Samples were placed directly on a
glass coverslip (Fisher Scientific), and an additional coverslip
was placed on top of the tissue in order to facilitate moderate
tissue compression. For image acquisition, a Zeiss multi-
photon confocal microscope (LSM 510 META NLO) was
used in tandem with a Coherent Chameleon femtosecond-
pulsed, mode-locked Ti: sapphire laser. This system was
set to operate as formerly described [23]. Specifically, an
excitation wavelength of 780 nm and a power setting of
10% maximum excitation power were used. The collected
emission wavelength range was 451–697 nm. Images were
collected at a magnification of 20x and a z-stack (depth)
increment of 5 µm. In order to calculate the percentage of
area covered by nanoshells, ImageJ imaging software was
implemented after image acquisition. Recent research has
shown that ImageJ can be used to analyze signal intensity
of silica-gold nanoshells under diﬀerent imaging systems
[11, 24]. Each pixel in the images had an intensity value in
the range of 0–255. To determine the nanoshell level in each
image, an intensity threshold of 30 was used to separate areas
that did not have nanoshells (≤30) from those that did have
nanoshells (>30). The value of 30 was chosen because images
of negative controls were found to have a maximum intensity
of 30. The number of pixels that were above the threshold
value was then used to calculate the area of each image that
contained nanoshells.
2.4. Darkfield Hyperspectral Imaging of Human Breast Tissue
Slices. To confirm the presence of nanoshells on the surface
of the tissues, HER2-positive cancerous, HER2-negative
cancerous and normal tissue samples were incubated with
nanoshells as previously described. A thin layer of patho-
logical ink was placed on the tissue surface for orientation.
The tissues were embedded in OCT media (BBC chemical)
and frozen rapidly over dry ice. The specimens were cut at a
section thickness of 8 µm using a Leica CM1850 UV cryostat.
Cancerous specimens were sectioned at −20◦C and normal
specimens at −30◦C. The diﬀerent temperatures were used
to maintain optimal tissue morphology as recommended by
Leica. Additionally, Magalha˜es et al. reported on the use of
diﬀerent temperatures to slice normal and cancerous tissue
[25]. The sections were immediately placed on superfrost
slides (Fisher Scientific) and allowed to dry overnight. The
next day the tissue slices were imaged with a 10x objective on
an Olympus darkfield microscope equipped with a Cytoviva
high-resolution illuminator. Hyperspectral images of the
tissue slices were taken using a hyperspectral camera that
provides both spatial and spectral data for each image.
Spectral data of each field of view (FOV) was used
to determine if nanoshells were present on each slice of
tissue. Comparisons were made between tissue surfaces and
tissue beyond the surfaces to determine the presence of
nanoshells; spectral data from tissue that was not incubated
with nanoshells was also used as a negative control.
2.5. Macroscopic Imaging of Human Breast Tissue Specimens.
Normal and HER2-positive cancerous breast tissue speci-
mens (from patients who had and had not received neoad-
juvant chemotherapy) were imaged using a Zeiss Discovery.
V8 stereomicroscope equipped with a VisiLEDMC1000 light
source. For macroscopic imaging of breast tissue specimens,
a thin plastic black stage was placed beneath a glass coverslip
to enable ease of tissue placement and to provide a consistent
black background among all samples. The specimens (con-
trols and respective nanoshell-labeled counterparts) were
placed alongside each other on top of the coverslip. Images
were taken at both 1x and 2x magnification under the same
lighting conditions.
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2.6. Reflectance Confocal Microscopy Imaging of Human Breast
Tissue Specimens. Following widefield imaging, the afore-
mentioned samples were prepared for microscopic analysis
under reflectance confocal microscopy. For this component
of the study, a Lucid VivaScope 2500 inverted confocal
microscope was used. Samples were placed directly on glass
slides that were modified by the addition of an adhesive
1mm deep, 20mm diameter silicon isolator (Invitrogen). To
compress the tissue slightly and consistently among samples,
an adhesive tissue cassette (Lucid, Inc.) was placed directly
on top of the silicone isolators above the tissue specimens.
Multiple images were taken at a power of 0.4mW and at
the same distance from the glass surface for both samples
and controls. After reflectance imaging, the samples were
prepared for histological processing. Additionally, reflectance
intensity measurements were recorded using ImageJ process-
ing software as formerly described [11].
2.7. Immunohistochemistry and Histology. Once images were
collected under both stereomicroscopy and RCM imaging
systems, normal and HER2-positive cancerous samples (with
and without previous neoadjuvant chemotherapy) were
embedded in OCT media and sectioned to a thickness of
5 µm. Multiple sections from each specimen were prepared
for either immunohistochemistry (IHC) or hematoxylin
and eosin (H&E) staining. IHC for the HER2 antigen was
executed using the Histostain Plus AEC Broad Spectrum Kit
(Invitrogen) per manufacturer’s instructions. H&E staining
was also performed per manufacturer’s instructions (Sigma
Aldrich) for the alcoholic Eosin Y solution. For image acqui-
sition, a standard brightfield microscope (Zeiss Axioskop 2
equipped with a Zeiss Axiocam MRc5 color camera) was
used at a magnification of 20x.
3. Results
3.1. Distribution and Penetration of Gold Nanoshells in Intact
Human Breast Tissue. The goal of this study was to evaluate
the distribution of anti-HER2-conjugated gold nanoshells
on resected intact tissue specimens. For comparison, the
nanoshell labeling between HER2-positive and HER2-
negative tissue samples was evaluated using a two-photon
imaging system. As previously reported, this imaging system
is capable of enhancing and capturing the luminescence
signature of the gold nanoshells [23] while also collecting
a stack of images taken through the depth of the tissue of
interest. Figure 2 represents such images of HER2-positive
and HER2-negative cancerous tissue samples incubated with
HER2-targeted nanoshells. Each sequential increment in the
z-direction represents 5 µm into the tissue. Qualitatively, the
first image (taken at the surface or at 0 µm) in Figure 2
demonstrates that the nanoshells preferentially label HER2
receptors on the surface of the tissue. Additionally, Figure 2
displays decreased signal as the focal spot from the confocal
microscope penetrates further into the tissue. This is believed
to be due to a minimal number of nanoshells being able
to penetrate the tissue in the limited amount of incubation
time, thus decreasing signal collected beyond the surface.
A quantitative diﬀerence of the nanoshell signal at the
surface of the HER2-positive and HER2-negative tissue was
calculated. Using ImageJ imaging software, it was determined
that approximately 66% of the FOV for HER2-positive tissue
was covered in nanoshells versus just 2% for the FOV of the
HER2-negative tissue. This confirms the preferential labeling
and visualization of HER2-positive tissue using anti-HER2
nanoshells.
To further validate the surface binding of the nanoshells,
hyperspectral images of diﬀerent tissue sections were also
acquired. Figure 3(a) shows a representative surface of a
HER2-positive tissue section after incubation with anti-
HER2 nanoshells. Figure 3(b) illustrates tissue 24 µmbeyond
the surface of the same tissue. Spectra from multiple (n = 3)
specimens that were incubated with anti-HER2 nanoshells
were acquired, and analysis showed that tissues without
nanoshells had very similar spectra across diﬀerent patients.
Figure 3(c) displays the respective spectral information of
each FOV shown in Figures 3(a) and 3(b). Additionally,
the spectra of HER2-positive tissue without nanoshells have
been included as a control. As can be seen in this graph, the
spectra of the surface of the HER2-positive tissue incubated
with anti-HER2 nanoshells are distinctive from that of the
same tissue 24 µm beyond the surface. In fact, the spectra
of the tissue beyond the surface of the nanoshell-labeled
specimen are very similar to the spectra of the surface of the
control. These results support our findings that the targeted
nanoshells primarily localized to the surface of the tissue.
3.2. Enhanced Optical Imaging of Intact Ex Vivo Human Breast
Cancer Tissue Using Gold Nanoshells. Based on previous
results demonstrating the preferential labeling of HER2-
targeted nanoshells on the surface of intact ex vivo HER2-
positive tissue specimens, we assessed the potential of using
a standard stereomicroscope to visualize this enhanced con-
trast. For this component of the study, human breast tissue
specimens that overexpressed HER2 receptors at the time of
patient diagnosis were evaluated and compared to normal
breast tissue. Due to the ultimate goal of utilizing gold
nanoshells to rapidly label tumor margins intraoperatively
in diverse patient populations, we examined tissue from
patients who had and had not undergone neoadjuvant
chemotherapy. All tissue samples were incubated with
either antibody diluent buﬀer or the anti-HER2-targeted
nanoshells for 5 minutes at 37◦C. As shown in Figure 4,
which represents raw images taken with a stereomicro-
scope, intact tissue specimens incubated with antibody
diluent alone showed no markings or features characteristic
of nanoshells. However, tissue specimens incubated with
the anti-HER2-targeted nanoshells demonstrate numerous
particles on the surfaces of the tissues. Qualitatively, the
HER2-positive tissue from the patient who did not undergo
previous chemotherapy shows the greatest labeling with
the targeted nanoshells. The HER2-positive tissue from the
patient who did undergo neoadjuvant chemotherapy does
demonstrate enriched nanoshell labeling when compared to
normal tissue, though not to the same extent as the patient
without previous chemotherapy. In contrast, the normal
tissue shows the least amount of nanoshell labeling, and only
a few areas of nanoshells can be visually perceived.
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Figure 2: Z-stack two-photon luminescence images of HER2-positive and HER2-negative tissue incubated with HER2-targeted nanoshells
for 5 minutes at 37◦C. Each progressive image represents an increase in depth penetration of 5 µm. Magnification = 20x. Scale bar = 50 µm.
While the degree of nanoshell labeling can be visualized
without image adjustments under a standard stereomicro-
scope, the superior extent of this labeling can be seen more
clearly after a simple contrast enhancement using imaging
software (ImageJ). As seen in Figure 5(a), the nanoshells
are even more discernable against the tissue background
regardless of inherent tissue constituents.
To validate the enhanced nanoshell labeling seen by
macroscopic imaging, the surfaces of the same tissue samples
were also imaged using reflectance confocal microscopy
(Figure 5(b)). Concurring with the stereomicroscopic
images, we see dramatic nanoshell surface labeling when
using targeted nanoshells with previously untreated HER2-
positive tissue. For the HER2-positive sample that had
formerly undergone chemotherapy, we also see enhanced
nanoshell labeling, though to a lesser degree than the
untreated sample as suggested by the stereomicroscopy
results. The normal breast tissue displays the least amount of
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Figure 3: Darkfield images of HER2-positive tissue sectioned after incubation with anti-HER2-targeted silica-gold nanoshells. (a) Surface
of HER2-positive tissue, (b) 24 µm beyond the surface of the same tissue. (c) Scattering spectra of the fields of view depicted in (a) and (b).
Additionally, spectra from the surface of HER2-positive tissue not incubated with silica-gold nanoshells are shown as a negative control.
Scale bar = 50 µm.
surface labeling with only minimal nanoshells evident with
either imaging system. Reflectance intensity measurements
(data not shown) were ∼2.5 to 3 times greater for both the
HER2-positive tissue sample receiving chemotherapy and
for the HER2-positive tissue not receiving chemotherapy
when compared to the normal tissue sample.
Subsequent histological analysis shown in Figure 5(c)
reveals that the distribution of HER2 receptors seen with
nanoshell-enabled contrast corresponds to that seen with
IHC against HER2. The HER2 expression seen by IHC is
greater for the previously untreated HER2-positive tissue
sample than for the sample that had undergone neoadjuvant
chemotherapy. This is believed to be due to the eﬀects of
chemotherapy. Rasbridge et al. previously demonstrated that
patient response to chemotherapy is highly variable, with
patients previously negative for HER2 overexpression occa-
sionally becoming positive after treatment and patients
previously positive for HER2 overexpression subsequently
becoming negative [26]. Although patient response to chem-
otherapy varies, tissues previously identified as overexpress-
ing HER2 receptors during initial diagnosis, regardless of
chemotherapy exposure, demonstrate enhanced nanoshell
labeling over normal tissue. Additionally, H&E-stained sec-
tions of all tissue samples have been included (Figure 5(d))
to illustrate the microscopic characteristics and diﬀerences
associated with cancerous versus noncancerous conditions.
Journal of Oncology 7
Buﬀer only HER2-targeted nanoshells
H
E
R
2 
po
si
ti
ve
, n
o 
ch
em
o
(a)
H
E
R
2 
po
si
ti
ve
, c
h
em
o
(b)
N
or
m
al
(c)
Figure 4: Raw stereomicroscope images of (a) and (b) HER2-overexpressing cancerous and (c) normal tissue incubated with either buﬀer
or HER2-targeted nanoshells for 5 minutes at 37◦C. Cancerous tissue taken from a patient (a) without chemotherapy and (b) following
neoadjuvant chemotherapy. Arrows represent nanoshells. Images taken at 2x. Scale bars = 2.5mm.
4. Discussion
In this study we demonstrated the ability to use targeted
gold nanoshells to rapidly improve visualization of a
specific biomarker associated with disease aggression and
progression (HER2) in intact ex vivo human breast tissue
and confirmed binding location via confocal and darkfield
hyperspectral microscopy. By utilizing silica-gold nanoshells
designed as rapid diagnostic imaging agents, surgeons and
pathologists may be able to realize tumor margin status
directly in the operating room after both macroscopic
and microscopic assessment. While multiple methods of
intraoperative tumor margin detection are currently under
investigation [27–31], we are developing an inexpensive and
portable system for rapidly analyzing ex vivo specimens based
on the desire to enhance current methodologies without
delay in clinical translation due to regulatory concerns
associated with in vivo systems.
The ability to enhance contrast of malignancy using
topically applied agents has previously been demonstrated
for oral and breast tissue using fluorescently labeled deoxy-
glucose and epidermal growth factor (EGF) conjugates [32–
34] as well as cervical tissue using fluorescently labeled
gold nanoparticles targeted to EGF receptors [35]. However,
these studies employed incubation times ranging from 20–
45 minutes, which exceeds the length of time currently
needed to obtain tumor margin status using frozen section
histology. Additionally, the aforementioned studies utilized
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Figure 5: (a) Stereomicroscopic images of HER2-overexpressing breast tissue (with and without neoadjuvant chemotherapy) and normal
breast tissue incubated with HER2-targeted nanoshells for 5 minutes at 37◦C after contrast enhancement. Magnification at 2x; scale bar =
2.5mm. Arrows represent nanoshells. (b) Respective reflectance confocal microscopy images of tissue samples from (a). Power = 0.4mW
and scale bar = 75 µm. Respective (c) HER2 immunohistochemistry and (d) H&E results taken under brightfield microscopy under 20x
magnification. Scale bar = 0.35mm.
optical clearing agents, which may be necessary for particles
that target intracellular biomarkers [36, 37]. Nevertheless,
gold nanoshells targeted to extracellular biomarkers may
oﬀer more favorable opportunities for ex vivo intraoperative
tumor margin detection without the need for lengthy
incubation times or the use of optical clearing agents.
Recently, we verified that silica-based gold nanoshells
could be used to enhance contrast of both HER2-over-
expressing cells and tissue sections within 5 minutes of
incubation time [10, 11]. However, translating this tech-
nology towards clinical relevancy requires the ability to
assess whole, unsectioned specimens. Here, we confirm that
gold nanoshells, when targeted to HER2 receptors, can
be used to distinguish intact HER2-overexpressing ex vivo
tissue from normal tissue within the same incubation time,
and we demonstrate that this diﬀerence can be observed
macroscopically. These results are supported by microscopic
imaging and immunohistochemistry against HER2.
By employing macroscopic imaging intraoperatively,
clinicians may be better able to distinguish cancerous and
normal breast tissue prior to further microscopic analysis
and subsequent histological processing. Ultimately, this
system could also be used for other diagnostic applications,
for other anatomical locations, and for other biomarkers
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associated with disease. By facilitating fast and accurate
tumor margin results intraoperatively as a supplement to
current diagnostic methods, we expect to reduce the amount
of time spent in surgery due to inadequate tissue removal.
To translate these findings more readily to the clinic,
we are presently developing a low-cost widefield imaging
system that can be used to detect the overexpression of
HER2 (and other extracellular biomarkers) through contrast
enhancement provided by gold nanoshells. In addition, we
plan to collect data from diverse patient populations and
assess results with fresh tissue samples. In this way, the use
of gold nanoshells may demonstrate widespread eﬃcacy or
be limited only to specific patient subsets.
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